Private Capital Advisors, Inc. Karyopharm Therapeutics Inc. Transaction History

Private Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 03, 2021	SELL	$9.85 - $17.69 $289,875 - $520,599	-29,429 Closed	0 $0
Q4 2020 Jan 15, 2021	BUY	$14.15 - $17.19 $416,420 - $505,884	29,429 New	29,429 $456,000
Q1 2020 Apr 15, 2020	SELL	$14.38 - $27.72 $1.5 Million - $2.89 Million	-104,100 Closed	0 $0
Q4 2019 Jan 09, 2020	SELL	$9.23 - $19.67 $121,374 - $258,660	-13,150 Reduced 11.22%	104,100 $2 Million
Q3 2019 Oct 15, 2019	SELL	$5.66 - $11.85 $2.32 Million - $4.85 Million	-409,650 Reduced 77.75%	117,250 $1.13 Million
Q2 2019 Jul 18, 2019	BUY	$4.32 - $6.43 $354,240 - $527,260	82,000 Added 18.43%	526,900 $3.16 Million
Q4 2018 Jan 14, 2019	SELL	$8.2 - $16.95 $237,808 - $491,566	-29,001 Reduced 6.12%	444,900 $4.17 Million
Q3 2018 Oct 16, 2018	BUY	$17.03 - $21.18 $8.07 Million - $10 Million	473,901 New	473,901 $8.07 Million
Q3 2018 Oct 12, 2018	SELL	$17.03 - $21.18 $7.1 Million - $8.83 Million	-416,900 Closed	0 $0
Q2 2018 Jul 10, 2018	BUY	$12.0 - $19.88 $5 Million - $8.29 Million	416,900 New	416,900 $7.08 Million

59.6M

547K

67K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $465M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Private Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Private Capital Advisors, Inc. with notifications on news.